Effect of lyophilization and storage temperature on the activity of salivaricin CRL 1328, a potential bioactive ingredient of a urogenital probiotic product.
Bacteriocins are antimicrobial peptides with potential applications as therapeutic agents for the treatment of microbial infections. The aim of this work was to investigate the effect of different protectors on the activity of salivaricin CRL1328, a bacteriocin produced by Lactobacillus salivarius CRL1328, during the lyophilization process and subsequent storage at different temperatures for 18 months using statistical models. Different protectors such as mannitol, Tween 80, polyethylene glycol 8000 (PEG), monosodium glutamate (MSG), reconstituted skim milk, sucrose and ascorbic acid were used for the lyophilization and storage of salivaricin. The biplot of principal component analysis was used for the interpretation of the interactions between the different factors studied. The antimicrobial activity of salivaricin was dependent mainly on temperature, and also on the time of storage and protector assayed. The stability of salivaricin was higher at -20°C and 4°C than 25°C and decreased during the time of storage; however, salivaricin was active after 18 months of storage at 25°C. Sucrose, mannitol plus sucrose, PEG plus sucrose and MSG were the most effective agents in protecting the bacteriocin during the lyophilization process. Effective maintenance of the activity of the bacteriocin was observed by storage with sucrose and ascorbic acid at -20°C as well as with PEG plus sucrose at 4°C and -20°C. The results obtained suggest that sucrose alone or combined with PEG can effectively maintain the activity of salivaricin during lyophilization and storage. This study provides useful information for the potential application of salivaricin as a bioactive principle for a pharmaceutical formulation.
Centro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145 (T4000ILC) San Miguel de Tucumán, Tucumán, Argentina.
Esteban
E
Vera Pingitore
Elena
E
Bru
Mar Iacutea
MI
Elena Nader-Macías
D001205:Ascorbic Acid / Q000494:pharmacology; D001430:Bacteriocins / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D004337:Drug Carriers / Q000494:pharmacology*; D004355:Drug Stability; D004356:Drug Storage / Q000379:methods*; D013293:Enterococcus faecalis / Q000187:drug effects*; D005260:Female; D005612:Freeze Drying / Q000379:methods*; D006801:Humans; D011092:Polyethylene Glycols / Q000494:pharmacology*; D025341:Principal Component Analysis; D019936:Probiotics; D013395:Sucrose / Q000494:pharmacology; D013696:Temperature; D014621:Vagina / Q000382:microbiology
D001430:Bacteriocins; D004337:Drug Carriers; C545224:salivaricin CRL 1328; D011092:Polyethylene Glycols; D013395:Sucrose; D001205:Ascorbic Acid